INDIA; UNITED STATES OF AMERICA —Novartis India Ltd has secured board authorization to acquire the domestic trademark rights and associated intellectual property for 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA. The total cash consideration for the transaction is set at approximately INR 12.5 billion. The asset purchase agreement and trademark assignment documentation were executed to enable simultaneous signing and closing of the deal.
Novartis India Ltd is a public pharmaceutical company that develops, markets, and distributes prescription medicines and healthcare products across India. Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation headquartered in the United States, producing a wide portfolio of therapies and vaccines. Pfizer Ltd operates as its public Indian subsidiary overseeing local product commercialization.
Following the brand transfer, Pfizer Ltd will cease the local sales, marketing, and distribution of Minipress XL, aligning with Pfizer Inc.'s broader strategic decision to halt manufacturing of the product line. Minipress XL, which contains prazosin, is used across the healthcare sector to manage hypertension and address urinary complications associated with benign prostatic hyperplasia. Industry tracking data through July 2026 indicates the product generated annual domestic revenue of INR 2,286 million, recording a four-year compound annual growth rate of 6.3 percent.
This portfolio realignment highlights a broader pharmaceutical trend where global drugmakers divest legacy mature brands to streamline manufacturing operations and optimize capital allocation. For Novartis, acquiring established cardiovascular and urology therapies consolidates its presence in stable chronic care markets across India. For healthcare providers and patients, the transaction ensures continuity of supply for long-established therapeutic formulations under a new pharmaceutical distributor.
